| Position | Action |
|---|---|
| Initial entry at $222.50 | Half-size position (1.5–2% of portfolio) |
| Pullback to $208–213 (10 EMA/VWMA confluence) | Add tranche with reserved dry powder |
| Confirmed hold above 50 SMA with MACD re-acceleration | Scale to full target weight (3–4% of portfolio) |
RTX presents a compelling BUY opportunity as all three moving averages confirm a structural uptrend (price $223.03 above 10 EMA 217.20, 50 SMA 194.84, and 200 SMA 188.50), fundamentals show accelerating revenue (+14.5% YoY), operating leverage (+31% YoY), and EPS growth (+122% from $2.23 to $4.96), while multiple hard-dated catalysts (SPY-6(V)4 delivery Aug 3, Patriot/THAAD acceleration, defense re-stockpiling, GTF aftermarket) provide asymmetric upside with limited downside risk.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 188.50 | bullish |
| close_50_sma | 194.84 | bullish |
| close_10_ema | 217.20 | bullish |
| rsi | 75.95 | bearish |
| macd | 8.16 | bullish |
| macds | 7.22 | bullish |
| macdh | 0.95 | bearish |
| boll_mid | 208.17 | neutral |
| boll_ub | 231.92 | bearish |
| boll_lb | 184.43 | bullish |
| atr | 5.17 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Overweight via Phased Entry: Half-Size at $222.50, Add at $208–213, Full Weight on 50 SMA Confirmation
The recommendation is Overweight (BUY) at the portfolio level, implemented through a trader's phased half-size entry at $222.50 with a hard stop at $194.84 (50 SMA). The structural case—Q2 +14.5% revenue growth, +31% operating income growth, ~111% FCF conversion, $8B YoY net debt reduction, and SPY-6/Patriot/SM-6/GTF catalysts—supports meaningful exposure. However, overbought RSI 75.95, MACD histogram decline from 2.17 to 0.95, and the Aug 7 lowest-volume buying climax on fresh highs warrant a risk-controlled approach. The phased plan—half-size core, reserved dry powder at $208–213 add zones, full weight on 50 SMA confirmation—honors structural conviction while respecting technical risk. Target $240–250 over 6–12 months. The $222.50 entry represents roughly 1:1 risk/reward to target, acceptable at half-size with max portfolio loss capped at 0.18–0.25%.
When: Price at $208–213 pullback zone (10 EMA/VWMA confluence)
Then: BUY with reserved dry powder
· concedes: RSI at 75.95 is elevated and overbought in oscillator terms; Price near upper Bollinger Band (231.92); MACD histogram easing from 2.17 to 0.95; Aug 7 volume at 2.1M shares was lowest of breakout window; Geopolitical ceasefire (90-98% through mid-August) has compressed missile defense urgency premium; 39x TTM P/E is above historical average; Urgency premium on defense spending has partially compressed
RTX at $223 is a negatively skewed risk/reward trade requiring perfection scenarios across EPS growth, GTF recovery, and defense backlog conversion, with valuation at 28x forward P/E, PEG of 2.78, and negative tangible book value creating structural vulnerability that makes this a "buy the dip" situation, not a "buy now" situation.
· concedes: The structural case is not wrong—it's early. The GTF recovery, defense super-cycle, and margin expansion will all play out over quarters and years.; The trend is intact for existing holders; hold with trailing stop rather than panic sell.; Pullbacks to $208–213 would make the bull case work better, giving better entries than $223.
→ vs conservative: Waiting for 50 SMA retest at $194 is a contradiction — demanding confirmation of strength through weakness when weakness to that level would actually break the trade thesis
→ vs conservative: The conservative path of waiting for confirmation means missing the stock rip another 7-12%
→ vs conservative: Asking to add only if trade proves you right by getting stopped out first means you don't get to have it both ways
→ vs neutral: Waiting for pullback to 213-217 during a momentum regime with defense prime catalysts is unlikely to provide clean retest of 10 EMA
→ vs neutral: The 'wait for better entry' advice is built on flawed premise that geopolitical premium is the entire bull case — it's not even half of it
→ vs neutral: Holding existing and waiting for pullback to 'accumulate on dips' at 50-day MA around $191 is anchoring to a moving average 14% below current price — by the time it gets to $210, stock could be at $240
| vwma | 213.78 | bullish |
Support: 184.43 · 188.5 · 194.84 · 208.17 · 213.78 · 217.2 | Resistance: 224.31 · 231.92
The market section analyzes RTX Corporation's technical setup on 2026-08-07, with price at 223.03 on volume of 2,100,622 shares. The primary trend is powerfully bullish with all moving averages properly stacked and rising (200 SMA at 188.50, 50 SMA at 194.84, 10 EMA at 217.20). Key caution flags include RSI at 75.95 (overbought), MACD histogram declining from 2.17 to 0.95 (momentum easing), price near the Bollinger upper band at 231.92, and the lowest volume session of the breakout landing on a new high. Key support zones are identified at 217.20 (10 EMA), 213.78 (VWMA), and 208.17 (20 SMA), with resistance at 224.31 (intraday high) and 231.92 (Bollinger UB). ATR stands at 5.17, suggesting ~$10 (2× ATR) stops for risk management. The recommended action is HOLD for existing positions with trailing stops near 215-217, while advising against initiating new longs until a pullback to the 213-217 zone offers better risk/reward.
Market Cap
$300.59B
Share Price
~$223
52-Week High
$224.31
52-Week Low
$150.61
50-Day Average
$191.28
200-Day Average
$188.14
P/E (TTM)
39.34
Forward P/E
28.40
PEG Ratio
2.78
Price/Book
4.53
Dividend Yield
1.31%
Beta
0.29
TTM Revenue
$93.5B
TTM EBITDA
$15.9B
Revenue (Q2 2026)
$24.71B
Revenue (2025)
$88.60B
Revenue (2024)
$80.74B
Revenue (2023)
$68.92B
Operating Income (Q2 2026)
$2.81B
Operating Income (2025)
$9.30B
Net Income (Q2 2026)
$2.14B
Net Income (2025)
$6.73B
Net Income (2024)
$4.77B
Net Income (2023)
$3.20B
Diluted EPS (Q2 2026)
$1.57
Diluted EPS (2025)
$4.96
Diluted EPS (2024)
$3.55
Diluted EPS (2023)
$2.23
Gross Margin (TTM)
20.3%
Operating Margin (TTM)
12.7%
Net Profit Margin (TTM)
8.3%
EBITDA Margin (TTM)
17.0%
ROE (TTM)
12.3%
ROA (TTM)
4.2%
Total Assets
$173.97B
Total Liabilities
$105.83B
Total Stockholders' Equity
$66.38B
Cash & Equivalents
$8.31B
Total Debt
$38.86B
Net Debt
$29.08B
Goodwill + Intangibles
$83.97B
Net Tangible Assets
($17.59B) — negative
Current Ratio
1.011
Working Capital
$0.67B
Long-Term Debt
$31.86B
Current Debt
$5.53B
Free Cash Flow (TTM)
$9.88B
Free Cash Flow (2025)
$7.45B
Free Cash Flow (2024)
$3.92B
Operating Cash Flow (TTM)
~$14.2B
Operating Cash Flow (2025)
$10.57B
CapEx (2025)
$3.12B
CapEx (annual)
~$3B/year (~3.3% of revenue)
Dividends Paid (2025)
$3.57B
FCF Yield
~3.3%
Revenue YoY (Q2 2026)
+14.5%
Revenue 3Y CAGR (2022–25)
~9.7%
EPS Growth (2023 → 2025)
2.23 → 4.96 (+122%)
Interest Expense (2025)
$1.84B
Net Debt Reduction YoY
~$8B
Debt/Equity
0.59x
Treasury Stock
$26.76B
Strengths
Concerns
The report concludes with a HOLD recommendation for RTX given strong fundamentals—accelerating revenue growth (+14.5% YoY to $24.71B in Q2 2026), recovering operating margins (12.7% TTM), and robust FCF expansion ($9.88B TTM)—offset by premium valuation (39x P/E) that already reflects much of the GTF recovery. The company has meaningfully deleveraged (net debt down $8B YoY) and shows improving cash flow quality (111% FCF conversion), but trading near 52-week highs suggests limited near-term upside. Long-term investors should accumulate on dips to the 50-day ($191) or 200-day ($188) moving averages.